Justin Walsh
Stock Analyst at B. Riley Securities
(1.85)
# 2,974
Out of 4,784 analysts
33
Total ratings
37.5%
Success rate
-9.35%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Maintains: Buy | $127 → $122 | $96.16 | +26.87% | 8 | Mar 21, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.29 | +107.94% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $2.27 | +692.95% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $10.05 | +317.91% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $1.50 | - | 2 | Oct 11, 2024 | |
| BLRX BioLineRx | Initiates: Buy | $80 | $3.05 | +2,522.95% | 1 | Sep 4, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $4.81 | +378.17% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.20 | +900.00% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $5.62 | +184.70% | 1 | May 10, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $20 | $2.78 | +619.42% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $1.00 | +300.00% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.99 | +905.03% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.75 | +2,290.76% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $3.58 | +12,190.50% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $1.16 | +6,365.52% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $26.21 | -23.69% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $2.32 | +8,520.69% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.99 | +402.51% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $9.60 | +8,233.33% | 1 | Sep 2, 2021 |
Lantheus Holdings
Mar 21, 2025
Maintains: Buy
Price Target: $127 → $122
Current: $96.16
Upside: +26.87%
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.29
Upside: +107.94%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $2.27
Upside: +692.95%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $10.05
Upside: +317.91%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.50
Upside: -
BioLineRx
Sep 4, 2024
Initiates: Buy
Price Target: $80
Current: $3.05
Upside: +2,522.95%
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $4.81
Upside: +378.17%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.20
Upside: +900.00%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $5.62
Upside: +184.70%
Achieve Life Sciences
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $2.78
Upside: +619.42%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $1.00
Upside: +300.00%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $1.99
Upside: +905.03%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $0.75
Upside: +2,290.76%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $3.58
Upside: +12,190.50%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $1.16
Upside: +6,365.52%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $26.21
Upside: -23.69%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $2.32
Upside: +8,520.69%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $1.99
Upside: +402.51%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $9.60
Upside: +8,233.33%